Amgen and AstraZeneca report Phase III Tezspire data for EoE
The trial evaluated 368 participants aged 12 to 80 years who were permitted to continue stable background therapies.
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Yahoo